Abstracts tagged "comparative effectiveness"

Abstract Number: 0817 • ACR Convergence 2023
Comparative Effectiveness of Yoga and Strengthening Exercise for Treating Knee OsteoArthritis: A Randomised Controlled Trial (YOGA Trial)
Bedru Abafita¹, Ambrish Singh¹, Dawn Aitken¹, Steffany Moonaz², Andrew J Palmer¹, Leigh Blizzard¹, Changhai Ding¹, Stan Drummen¹, Graeme Jones³, Kim Bennell⁴ and Benny Samuel Antony¹, ¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ²Department of Clinical and Health Services Research, Southern California University of Health Sciences, Whittier, CA, ³Menzies Institute for Medical Research, University of Tasmania, Melbourne, Australia, ⁴University of Melbourne, Melbourne, Australia
Background/Purpose: There is uncertainty about the best type of exercise to optimise outcomes for people with knee osteoarthritis (OA). Strengthening exercise is commonly recommended. However,…
Abstract Number: 0831 • ACR Convergence 2023
Two- and Three-Year Outcomes from the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study
Sarah Ringold¹, George Tomlinson², Laura Schanberg³, vincent del gaizo⁴, Katherine Murphy⁵, Brian Feldman⁶, Mei-Sing Ong⁷, Marc Natter⁸, Yukiko Kimura⁹ and For The CARRA Registry Investgators⁴, ¹Seattle Children's Hospital, Seattle, WA, ²University of Toronto, Toronto, ON, Canada, ³Duke University School of Medicine, Durham, NC, ⁴CARRA, Inc, Washington, DC, ⁵Non-clinical, New Orleans, LA, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ⁸Harvard Medical School, Boston, MA, ⁹Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: The STOP-JIA study was designed to compare the effectiveness of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Consensus Treatment Plans (CTPs) for untreated…
Abstract Number: 0973 • ACR Convergence 2023
Real-World Comparative Effectiveness Study of Janus Kinase Inhibitors Compared to Biologic Disease Modifying Antirheumatic Drugs in Korean Patients with Rheumatoid Arthritis
Soo-Kyung Cho¹, Yeo-Jin Song¹, Jungyong Han², Hye Won Kim³, Eunwoo Nam³, Sang Won Lee⁴, Shin-Seok Lee⁵, Hye-Soon Lee⁶, Sung-Hoon Park⁷, Yeon-Ah Lee⁸, Sung Hae Chang⁹, Min-Chan Park¹⁰, Hyoun-Ah Kim¹¹, Hyun-Sook Kim¹², Bo Young Yoon¹³, Yong-Gil Kim¹⁴, Hae-Rim Kim¹⁵, Jae Hoon Kim¹⁶, Jisoo Lee¹⁷, Jeongim Choi¹⁸, Wan-Sik Uhm¹⁹ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Hanyang University Institute for Rheumatology Research, Seoul, South Korea, ⁴Hanyang University, Seoul, South Korea, ⁵Chonnam National University Medical School & Hospital, Gwangju, South Korea, ⁶Hanyang University, Guri, South Korea, ⁷Daegu Catholic University School of Medicine, Daegu, South Korea, ⁸Kyung Hee University Hospital, Seoul, South Korea, ⁹Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, ¹⁰Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, ¹¹Ajou University School of Medicine, Suwon, South Korea, ¹²Soonchunhyang University Seoul Hospital, Seoul, South Korea, ¹³Inje University Ilsan Paik Hospital, Goyang, South Korea, ¹⁴Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ¹⁵Rheumatology, Konkuk University Medical Center, Seoul, South Korea, ¹⁶Korea University Medical Center, Seoul, South Korea, ¹⁷Ewha Womans Univ College of Medicine, Seoul, South Korea, ¹⁸Busan Saint Mary's Hospital, Busan, South Korea, ¹⁹Uhm's Rheumatism Clinic, Seoul, South Korea
Background/Purpose: Although clinical trials have shown similar effectiveness between Janus kinase inhibitors (JAKi) and biologic disease-modifying anti-rheumatic drugs (bDMARDs), the choice between these two options…
Abstract Number: 1117 • ACR Convergence 2023
Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis
Chio Yokose¹, Gregory Challener², Baijun Zhou², Natalie McCormick², Sruthi Tanikella², Kila Panchot², Minna Kohler³, Janeth Yinh², Yuqing Zhang⁴, David Bates⁵, James Januzzi², Meghan Sise², Deborah Wexler² and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are currently indicated as second-line therapy for type 2 diabetes and are also approved for the treatment of…
Abstract Number: 062 • 2023 Pediatric Rheumatology Symposium
Assessment of Barriers and Facilitators in Implementation of the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
Cagri Yildirim-Toruner¹, Daniel Glaser², Timothy Beukelman³, Stacy Ardoin⁴, Ahmar Hashmi⁵, Rajdeep Pooni⁶, Maria Fernandez⁵, Vincent Del Gaizo⁷, Leslie Hanrahan⁷, Mary Ellen Riordan⁸, Stacey Tarvin⁹ and CARRA Registry Investigators⁷, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Yale University School of Medicine, New Haven, CT, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵The University of Texas Health Sciences Center at Houston, Institute for Implementation Science, Houston, TX, ⁶Stanford University, Palo Alto, CA, ⁷CARRA, Washington, DC, ⁸Hackensack Meridian Health/ Joseph M. Sanzari Children's Hospital, Hackensack, NJ, ⁹Riley Hospital for Children at Indiana University Health, Indianapolis, IN
Background/Purpose: Since 2010, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) has developed 12 consensus treatment plans (CTP) with the aim of reducing treatment variability…
Abstract Number: 1084 • ACR Convergence 2022
Rituximab versus Cyclophosphamide for Induction Therapy in Granulomatosis with Polyangiitis: A Target Trial Emulation Study
Xavier Puéchal¹, Michele Iudici², Elodie Perrodeau³, bernard bonnotte⁴, Francois Lifermann⁵, Thomas Le Gallou⁶, Alexandre Karras⁷, Claire Blanchard-Delaunay⁸, Thomas Quéméneur⁹, Achille Aouba¹⁰, Olivier Aumaître¹¹, Vincent Cottin¹², Mohamed Hamidou¹³, Marc Ruivard¹¹, Pascal Cohen¹, Luc Mouthon¹, Loïc Guillevin¹, Philippe Ravaud³, Raphaël Porcher³ and Benjamin Terrier¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ³Université Paris Cité, Hôtel-Dieu, Paris, France, ⁴Centre Hospitalo-Universitaire de Dijon, Dijon, France, ⁵Dax Hospital, Dax, France, ⁶Rennes Sud University Hospital, Rennes, France, ⁷HEGP, Paris, France, ⁸Niort Hospital, Niort, France, ⁹Valenciennes Hospital, Valenciennes, France, ¹⁰Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, ¹¹Clermont Ferrand University Hospital, Clermont-Ferrand, France, ¹²Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ¹³Nantes University Hospital, Nantes, France
Background/Purpose: Randomized controlled trials showed rituximab (RTX)'s non-inferiority to cyclophosphamide (CYC) for induction therapy of ANCA-associated vasculitis and neither treatment was favoured in granulomatosis with…
Abstract Number: 1430 • ACR Convergence 2022
Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis
Cristiano Moura¹, Luck Lukusa¹, Laura Yan¹, Walter P Maksymowych², Denis Choquette³, Gilles Boire⁴ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: The first biosimilar etanercept (ETA-B) was approved in Canada in 2016, but real-world data comparing the effectiveness of ETA-B versus its equivalent originator (ETA-O)…
Abstract Number: 1432 • ACR Convergence 2022
Pharmacokinetic Evaluation of a Proposed Adalimumab Biosimilar MSB11022 versus the US-Licensed Reference Product: Results of a Randomized, Double-Blind, 3-Arm Parallel-Group, Single-Dose Trial in Healthy Subjects
Anna Dryja¹, Anna Lucia Buccarello², Isabelle Gaillard² and Joëlle Monnet², ¹MTZ Clinical Research Sp. z o.o.,, Warsaw, Poland, ²Fresenius Kabi Swiss BioSim, Eysins, Switzerland
Background/Purpose: Adalimumab, a recombinant fully human monoclonal immunoglobulin G1 antibody, is a biologic directed against tumor necrosis factor-alpha indicated for use in a range of…
Abstract Number: 1669 • ACR Convergence 2022
Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis
Anne Bass¹, Noha Abdel-Wahab², Pankti Reid³, Jeffrey Sparks⁴, Cassandra Calabrese⁵, Deanna Jannat-Khah, DrPH, MSPH⁶, Diviya Rajesh⁶, Nilasha Ghosh⁶, Komal Mushtaq⁷, Farah Al Haj⁸, Adewunmi Falohun⁹, Lydia Gedmintas¹⁰, Lindsey MacFarlane¹¹, Senada Arabelovic¹¹, Adi Diab², Ami Shah¹², Clifton O. Bingham III¹³, Karmela Kim Chan⁶ and Laura C. Cappelli¹⁴, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²UT MD Anderson Cancer Center, Houston, TX, ³University of Chicago Medical Center, Chicago, IL, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Cleveland Clinic Foundation, Cleveland Heights, OH, ⁶Hospital for Special Surgery, New York, NY, ⁷Cleveland Clinic, Cleveland, OH, ⁸Sinai Grace Hospital/ Detroit Medical Center, Detroit, MI, ⁹MD Anderson Cancer Center, Houston, TX, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitor associated arthritis (ICI-A) affects ∼4% of ICI-treated cancer patients and often persists. Given its long duration, it is important to identify…
Abstract Number: 1679 • ACR Convergence 2022
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: Three-Year Outcomes
Yukiko Kimura¹, Sarah Ringold², George Tomlinson³, Laura Schanberg⁴, Anne Dennos⁵, MaryEllen Riordan⁶, Vincent Del Gaizo⁷, Katherine Murphy⁸, Pamela Weiss⁹, Brian Feldman¹⁰, Mei Sing Ong¹¹ and Marc Natter¹², ¹Hackensack Meridian Health, New York, NY, ²Janssen, Seattle, WA, ³University of Toronto, Toronto, ON, Canada, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Hackensack Meridian Health, Hackensack, NJ, ⁷CARRA, Inc, Washington, DC, ⁸CARRA, Inc, New Orleans, LA, ⁹Children's Hospital of Philadelphia, Glen Mills, PA, ¹⁰Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹¹Harvard Pilgrim Institute, Boston, MA, ¹²Boston Children's Hospital, Boston, MA
Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinically inactive disease (CID) in untreated polyarticular JIA…
Abstract Number: 1841 • ACR Convergence 2022
To Combine or Not to Combine: Influence of Immunosuppressive Drug Combination in the Induction of Therapeutic Response in Non-infectious Uveitis
María Paula Álvarez Hernández¹, Alfredo Madrid-García², Alejandro Gómez Gómez³, Lara Borrego Sanz⁴, Rosalía Méndez Fernández⁴, Pedro Arriola Villalobos⁴, Esperanza Pato Cour⁵, David Díaz Valle⁴ and Luis Rodriguez-Rodriguez⁵, ¹Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, Madrid, Spain, ³Hospital Infanta Sofia, Rheumatology, San Sebastián de los Reyes, Madrid, Spain, ⁴Instituto de Investigación Sanitaria San Carlos, Ophthalmology, Madrid, Spain, ⁵Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain
Background/Purpose: Non-infectious uveitides (NIUs) include a heterogeneous group of sight-threatening and incapacitating conditions. Their correct management sometimes requires the use of immunosuppressive drugs (ISDs), prescribed…
Abstract Number: 0058 • ACR Convergence 2022
Health System Improvement in Inpatient ANA and Serologic Test Utilization
Saloni Goyal¹, Yasin kanakrieh¹, Marie O'Brien¹, Amy Slenker¹, Kathryn Zaffiri¹ and James Ross², ¹Lehigh Valley Health Network, Allentown, PA, ²lvhn, Macungie, PA
Background/Purpose: In 2005 Lehigh Valley Health Network (LVHN) instituted order sets for ANA serologic reflex testing with the objective to facilitate more efficient patient work-up…
Abstract Number: 0133 • ACR Convergence 2022
Retention Rate of Targeted Therapies in Erdheim-Chester Disease
Corrado Campochiaro¹, alessandro tomelleri¹, Francesco Pegoraro², Giovanni Galardi³, Nicola Farina⁴, Martina Mazzariol⁵, Francesco Catamerò⁶, Giacomo De Luca⁴, Giulio Cavalli⁴, Augusto Vaglio⁷ and Lorenzo Dagna⁸, ¹IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milano, Italy, ²Department of Health Sciences, University of Florence, Firenze, Italy, ³Department of Health Sciences, University of Florence, Florence, Italy, ⁴IRCCS San Raffaele Hospital - Vita-Salute San Raffaele University, Milano, Italy, ⁵University of Turin, Torino, Italy, ⁶Vita-Salute San Raffaele University, Milano, Italy, ⁷Azienda Ospedaliero Universitaria Meyer, Parna, Italy, ⁸IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milano, Italy
Background/Purpose: Erdheim-Chester disease (ECD) is a rare non-Langerhans histiocytosis with a broad clinical spectrum. The therapeutic landscape of ECD has remarkably changed over the last…
Abstract Number: 0576 • ACR Convergence 2022
Comparative Effectiveness of Osteoporosis (OP) Therapies Among a Population of Postmenopausal (PM) Women in the United States (U.S.)
Min Kim¹, Leah J McGrath², David Pritchard², Peter Samai², Jay Lin¹, Robert Kees Stad³, Leslie Spangler¹, Michele McDermott¹, Brian D Bradbury⁴ and M Alan Brookhart², ¹Amgen, Inc., Thousand Oaks, CA, ²NoviSci, Inc., Durham, NC, ³Amgen Inc., Zug, Switzerland, ⁴Amgen Inc., 1 Amgen Center Drive
Background/Purpose: Although clinical trials evaluating the efficacy of osteoporosis (OP) therapies have shown that denosumab (Dmab) significantly increases bone mineral density at pivotal sites compared…
Abstract Number: 0714 • ACR Convergence 2022
Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
Yinzhu Jin, Jun Liu, Rishi Desai and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Serostatus may be associated with different responses to treatment with biologic disease-modifying anti-rheumatic drugs (DMARD) or Janus kinase inhibitors (JAKi) in patients with rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].